You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

Havrix Junior helps provide rapid and long-term protection from hepatitis A1–3

50 Years Icon

Up to 50 years’ predicted long-term protection when administered in paediatric populations*3

100% icon

100% seroconversion within 14 days of vaccination**1 (acute hepatitis A incubation period usually 15–50 days)4

[LOCs to update number of days in seroconversion claim when appropriate, to align with local SmPC]

[LOCs to check coadministration options against their local PI]

Havrix Junior for children and adolescents aged ≤15 years can be co-administered with a wide range of other vaccines:2,5

  1. Typhoid
  2. Yellow fever
  3. Cholera (injectable)
  4. Tetanus
  5. Measles, mumps and rubella
  6. Varicella
Vaccination Icon

Havrix Junior has a two-dose regimen2

For children/adolescents aged 1–15 years2

[LOCs to update as per the therapeutic indication of Havrix Junior in the local SmPC]

Immunisation Vaccine

Primary immunisation schedule

Given as a single dose, intramuscularly2

Booster Dose Icon

Booster dose

  • Recommended between 6 and 12 months after the primary dose†2
  • Where this is not possible, booster can be delayed up to 3 years[LOCs to update the booster delay timeline as per local SmPC]
  • Given as a single dose, intramuscularly2

Havrix (Adult and Junior) has extensive clinical and real-world experience6,7

  • The world’s first licensed vaccine against hepatitis A6
  • 30 years of real-world experience6
  • Registered in >85 countries7
  • ~400 million doses†† distributed worldwide since its launch in 19927
  • The world’s most widely studied hepatitis A vaccine6
  • 150 clinical trials involving >30,000 subjects6

CI, confidence interval; UV, universal vaccination; mIU/mL, milli-international units per millilitre

*A descriptive analysis was used to predict long-term seropositivity results for children based on studies of vaccines containing inactivated hepatitis A antigen either as standalone hepatitis A vaccine or combination hepatitis A and B vaccine. In order to extrapolate outcomes in children using data in adults, studies with data on adult vaccine doses of hepatitis A and B vaccine 720 EU or hepatitis A vaccine 1,440 EU were selected3
**138 mIU/mL (95% CI: 120–159). In a comparative trial in which 332 seronegative children from 1–15 years of age were randomised to receive two doses of hepatitis A vaccine 6 months apart1
Havrix Junior can be administered to children and adolescents aged 1–15 years.2 Havrix Junior is administered in a primary dose with a booster dose recommended 6 to 12 months after primary immunisation. Havrix Junior provides active immunisation against infections caused by hepatitis A in both age groups2
††In both paediatric and adult populations7


  1. Abarca K et al. Int J Infect Dis 2008; 12:270–277.
  2. Havrix Junior SmPC, January 2022.
  3. Agrawal A et al. Infect Dis Ther 2020; 9:785–796.
  4. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases (The Pink Book). 14th Edition. 2021. Public Health Foundation, Washington, D.C.; p.125–142.
  5. Havrix Global Data Sheet, December 2019.
  6. André F et al. Expert Rev Vaccines 2002; 1:9–23.
  7. GSK data on file; 2023N531266_00.

For more information, please refer to the prescribing information or contact GlaxoSmithKline
To report Adverse Event/s associated with the use of GSK product/s, please contact us via
To report quality complaint/s associated with the use of GSK product/s, please contact us via

GlaxoSmithKline Biologicals SA. Rixensart, Belgium
© 2023 GSK group of companies or its licensor
Trademark is owned by or licensed to the GSK group of companies

PM-RCH-HAV-WCNT-230002 | Date of preparation: November 2023